Search
AVITA Medical Inc
RCELAdd to Watchlist
11.580USD
+0.630+5.75%
Close 09-24 16:00（ET）
356.43MMarket Cap
LossP/E TTM
About AVITA Medical Inc Company
AVITA Medical, Inc. is a therapeutic acute wound care company. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.
AVITA Medical Inc Profile
Ticker SymbolRCEL
Company nameAVITA Medical Inc
IPO dateMar 18, 2012
CEOVance (Cary G)
Number of employees260
Security typeOrdinary Share
Fiscal year-endMar 18
Address28159 Avenue Stanford
CityVALENCIA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code91355
Phone16613679170
Websitehttps://www.avitamedical.com/
Ticker SymbolRCEL
IPO dateMar 18, 2012
CEOVance (Cary G)
Company Executives of AVITA Medical Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph Fralin (Joe) Woody
Mr. Joseph Fralin (Joe) Woody
Non-Executive Director
Non-Executive Director
107.96K
+41.87%
Mr. Joseph Fralin (Joe) Woody
Mr. Joseph Fralin (Joe) Woody
Non-Executive Director
Non-Executive Director
107.96K
+41.87%
Prof. Suzanne Crowe
Prof. Suzanne Crowe
Independent Non-Executive Director
Independent Non-Executive Director
46.93K
-6.37%
Prof. Suzanne Crowe
Prof. Suzanne Crowe
Independent Non-Executive Director
Independent Non-Executive Director
46.93K
-6.37%
Mr. Jeremy Curnock Cook
Mr. Jeremy Curnock Cook
Independent Non-Executive Director
Independent Non-Executive Director
39.84K
-7.51%
Mr. Jeremy Curnock Cook
Mr. Jeremy Curnock Cook
Independent Non-Executive Director
Independent Non-Executive Director
39.84K
-7.51%
Ms. Jan Stern Reed
Ms. Jan Stern Reed
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Mr. Cary G. Vance
Mr. Cary G. Vance
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Mr. Robert E. Mcnamara
Mr. Robert E. Mcnamara
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. David O'Toole
Mr. David O'Toole
Chief Financial Officer
Chief Financial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph Fralin (Joe) Woody
Mr. Joseph Fralin (Joe) Woody
Non-Executive Director
Non-Executive Director
107.96K
+41.87%
Mr. Joseph Fralin (Joe) Woody
Mr. Joseph Fralin (Joe) Woody
Non-Executive Director
Non-Executive Director
107.96K
+41.87%
Prof. Suzanne Crowe
Prof. Suzanne Crowe
Independent Non-Executive Director
Independent Non-Executive Director
46.93K
-6.37%
Prof. Suzanne Crowe
Prof. Suzanne Crowe
Independent Non-Executive Director
Independent Non-Executive Director
46.93K
-6.37%
Mr. Jeremy Curnock Cook
Mr. Jeremy Curnock Cook
Independent Non-Executive Director
Independent Non-Executive Director
39.84K
-7.51%
Mr. Jeremy Curnock Cook
Mr. Jeremy Curnock Cook
Independent Non-Executive Director
Independent Non-Executive Director
39.84K
-7.51%
FAQs
Who are the top five shareholders of AVITA Medical Inc?
The top five shareholders of AVITA Medical Inc are: Mr. Joseph Fralin (Joe) Woody
How many institutions hold shares of AVITA Medical Inc (RCEL)?
As of 2026Q1, 209 institutions hold shares of AVITA Medical Inc, with a combined market value of approximately 6.52M, accounting for 21.20% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -1392153.00.